Abstract
Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Current Neuropharmacology
Title: PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Volume: 4 Issue: 3
Author(s): Yuan-Xiang Tao and Roger A. Johns
Affiliation:
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Abstract: Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Export Options
About this article
Cite this article as:
Tao Yuan-Xiang and Johns A. Roger, PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment, Current Neuropharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157015906778019473
DOI https://dx.doi.org/10.2174/157015906778019473 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration
Current Cancer Drug Targets Editorial
Recent Patents on CNS Drug Discovery (Discontinued) GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Current Medicinal Chemistry Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Anesthetics as Chemical Tools to Study the Structure and Function of Nicotinic Acetylcholine Receptors
Current Protein & Peptide Science Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Current Neuropharmacology Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism PET and SPECT Imaging of the NMDA Receptor System: An Overview of Radiotracer Development
Mini-Reviews in Medicinal Chemistry Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Current Neuropharmacology Structure-to-function Relationship of Carbohydrates in the Mechanism of Lysosomal Storage Disorders (LSDs)
Current Organic Chemistry Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews Editorial [Hot Topic: Glutamate Receptors and Related Processes as Drug Targets (Guest Editor: Michel Baudry)]
Current Drug Targets Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Current Pharmaceutical Design Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews